{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Protocol amendment summary of change table', 'Section # and Name', 'Description of', 'Brief Rationale', 'Change', 'Clinical Trial Summary', 'Change of primary efficacy', '11.3.1 Analysis population', 'analysis population from', 'full intent-to-treat (ITT) to', '11.4.2.1 Analysis of Primary', 'patients with either \"asthma', 'Efficacy Endpoint(s)', 'with an eosinophilic', '11.4.2.2 Analyses of', 'phenotype\" or with \"asthma', 'Secondary Efficacy', 'with type 2 inflammatory', 'Endpoints', 'phenotype\".', '4 Introduction and Rationale', 'Description of type 2', 'To support the change of primary efficacy analysis population', 'inflammatory phenotype', 'population', 'Property of the Sanofi Group - strictly confidential', 'Page 4', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Clinical trial summary', 'Change of study sample', 'The population of interest is asthma patients with either \"asthma', '1 Flow chart', 'size.', 'with an eosinophilic phenotype\" or \"asthma with type 2', '1.1 Overview of study design', 'inflammatory phenotype\" based on the observed efficacy from', 'the QUEST study and on the approved indications in different', '11.1 Determination of', 'regions. With regard to these populations, the sponsor has', 'sample size', 'designated a primary analysis population and additional', 'secondary analysis populations based on these two populations', 'of interest. The sponsor has updated the sample size needed to', 'demonstrate efficacy based on these definitions for the primary', 'analysis populations.', 'The sample size calculation assumes a linear discontinuation', 'rate (20% at 1 year), thus the average exposure duration for', 'patients is 0.9 year.', 'Property of the Sanofi Group - strictly confidential', 'Page 5', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Section # and Name', 'Description of', 'Brief Rationale', 'Change', 'Clinical trial summary', 'To specify that different', '11.4.2.3 Multiplicity', 'hierarchy orders are to be', 'considerations', 'used for US and US', 'reference countries and EU', 'and EU reference', 'countries.', 'Clinical trial summary', 'Removal of the limit in', '8.4 Method of assigning', 'enrolling patients according', 'patients to treatment group', 'to background therapy with', 'medium-dose ICS or blood', '11.1 Determination of', 'eosinophil count level', 'sample size', 'Property of the Sanofi Group - strictly confidential', 'Page 6', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}